Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reissue Patent
2004-05-21
2010-10-26
Helms, Larry R (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S085100, C424S198100, C435S069500, C435S039000, C435S325000, C435S334000
Reissue Patent
active
RE041887
ABSTRACT:
The present invention features a novel combination therapy useful in the treatment of autoimmune disease that increases or maintains the number of functional cells of a predetermined type in a mammal by killing or inactivating autoimmune cells and re-educating the host immune system.
REFERENCES:
patent: 4309418 (1982-01-01), Green
patent: 4457916 (1984-07-01), Hayashi et al.
patent: 4495282 (1985-01-01), Ohnishi et al.
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4681760 (1987-07-01), Fathman
patent: 4791101 (1988-12-01), Adolf
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4879226 (1989-11-01), Wallace et al.
patent: 4963354 (1990-10-01), Shepard et al.
patent: 4985241 (1991-01-01), Zimmerman et al.
patent: 5002876 (1991-03-01), Sreekrishna et al.
patent: 5059530 (1991-10-01), Oshima et al.
patent: 5139481 (1992-08-01), Faustman et al.
patent: 5215743 (1993-06-01), Singh et al.
patent: 5283058 (1994-02-01), Faustman
patent: 5288852 (1994-02-01), Yamada et al.
patent: 5487984 (1996-01-01), Allet et al.
patent: 5538854 (1996-07-01), Faustman
patent: 5560908 (1996-10-01), Satoh et al.
patent: 5593698 (1997-01-01), Weiner et al.
patent: 5783216 (1998-07-01), Faustman
patent: 5821337 (1998-10-01), Carter et al.
patent: 5843425 (1998-12-01), Sachs et al.
patent: 5843452 (1998-12-01), Wiedmann et al.
patent: 5874306 (1999-02-01), Beattie et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 6046031 (2000-04-01), Ni et al.
patent: 6056952 (2000-05-01), Rosenberg
patent: 6165737 (2000-12-01), Wang et al.
patent: 6284879 (2001-09-01), Faustman
patent: 6414218 (2002-07-01), Faustman et al.
patent: 6420139 (2002-07-01), Classen
patent: 6491908 (2002-12-01), Rosenberg
patent: 6599710 (2003-07-01), Faustman
patent: 6617171 (2003-09-01), Faustman et al.
patent: 6660487 (2003-12-01), Faustman
patent: 6773705 (2004-08-01), Faustman et al.
patent: 6844011 (2005-01-01), Faustman
patent: 6866843 (2005-03-01), Habener et al.
patent: 6923959 (2005-08-01), Habener et al.
patent: 6984380 (2006-01-01), Faustman
patent: 2002/0106689 (2002-08-01), Faustman et al.
patent: 2002/0123472 (2002-09-01), Faustman
patent: 2003/0005469 (2003-01-01), Faustman et al.
patent: 2003/0031657 (2003-02-01), Habener et al.
patent: 2004/0028658 (2004-02-01), Faustman
patent: 2004/0031066 (2004-02-01), Faustman et al.
patent: 2004/0229785 (2004-11-01), Faustman
patent: 2005/0158288 (2005-07-01), Faustman
patent: 2005/0158302 (2005-07-01), Faustman et al.
patent: 2005/0244386 (2005-11-01), Habener et al.
patent: 2006/0062769 (2006-03-01), Habener et al.
patent: 2007/0116688 (2007-05-01), Faustman
patent: WO 95/24914 (1995-09-01), None
patent: WO 95/25533 (1995-09-01), None
patent: WO 97/08328 (1997-03-01), None
patent: WO 00/53209 (2000-09-01), None
patent: WO 02/26819 (2002-04-01), None
Shehadeh et al. (Isr J Med Sci. 1997, vol. 33, p. 711-715 in IDS of Jul. 22, 2009.
Shahedeh et al. (The Lancet, 1994, vol. 343, p. 706-707).
Elliot et al. (Diabetes Care, Oct. 1998, p. 1691-1693).
Rabinovitch J Autoimmunity 1995, vol. 8, p. 357-366.
Totpal et al. (Journal of Immunology, 1994, vol. 153, p. 2248-2257.
Rajagopalan et al., PNAS 1990, vol. 87, p. 7020-7024.
Rabinovitch et al. Journal of Immunology, 1997, vol. 159, p. 6298-6303.
Serrano et al. Autoimmunity Reviews, 2006, vol. 5, p. 209-214.
Altmonte et al. Clinical rheumatology, 1992, vol. 11, p. 202-205.
Marriott, Exp. Opin. Invest. Drugs, 1997, vol. 6, p. 1105-1108.
Kawasaki et al. Diabetes research and clincial practice, 2004, vol. 66, p. 27-32.
Chaim et al. PNAS, 1990, vol. 87, p. 968-972.
Von Herrath et al., “In Vivo Treatment with a MHC Class I-Restricted Blocking Peptide Can Prevent Virus-Induced Autoimmune Diabetes,”J. Immunol.161(9):5087-5096 (1998).
Baik et al., “BCG Vaccine Prevents Insulitis in Low Dose Streptozotocin-Induced Diabetic Mice,”Diabetes Research and Clinical Practice46:91-97 (1999).
Brás et al., “Diabetes-Prone NOD Mice are Resistant toMycobacterium aviumand the infection Prevents Autoimmune Disease,”Immunology89:20-25 (1996).
Cavallo et al., “BCG Vaccine With and Without Nicotinamide in Recent Onset IDDM: A Multicenter Randomized Trial,”Autoimmunity24(Suppl. 1):A063 (1996).
Choi et al., “Prevention of Encephalomyocarditis Virus-Induced Diabetes by Live RecombinantMycobacterium bovisBacillus Calmette-Guérin in Susceptible Mice,”Diabetes49:1459-1467 (2000).
Gazda et al.,“Regulation of Autoimmune Diabetes: Characteristics of Non-Islet-Antigen Specific Therapies,”Immunology and Cell Biology74:401-407 (1996).
Harada et al., “Prevention of Overt Diabetes and Insulitis in NOD Mice by a Single BCG Vaccination,”Diabetes Research and Clinical Practice8:85-89 (1990).
Horsfall et al., “Characterizaton and Specificity of B-Cell Responses in Lupus Induced byMycobacterium bovisin NOD/Lt mice,”Immunology95:8-17 (1998).
Horwitz et al., “Recombinant Baccillus Calmette-Guérin (BCG) Vaccines Expressing theMycobacterium tuberculosis30-kDa Major Secretory Protein Induce Greater Protective Immunity Against Tuberculosis Than Conventional BCG Vaccines in a Highly Susceptible Animal Model,”Proceedings of the National Academy of Sciences97(25):13853-13858 (2000).
Klingensmith et al., “Vaccination with BCG at Diagnosis Does Not Alter the Course of IDDM,” Abstract Presented at the 31stResearch Symposium on Prevention of Type I Diabetes in General Population. American Diabetes Association, Estes Park, Colorado, 27-29 (1996).
Qin and Singh, “BCG Vaccination Prevents Insulin-Dependent Diabetes Mellitus (IDDM) in NOD Mice After Disease Acceleration with Cyclophosphamide,”Journal of Autoimmunity10:271-278 (1997).
Ristori et al., “Use of Bacille Calmette-Guérin (BCG) in Multiple Sclerosis,”Neurology53:1588-1589 (1999).
Serreze et al., “Th1 to Th2 Cytokine Shifts in Nonobese Diabetic Mice: Sometimes an Outcome, Rather than the Cause, of Diabetes Resistance Elicited by Immunostimulation,”The Journal of Immunology166:1352-1359 (2001).
Shehadeh et al., “Repeated BCG Vaccination is More Effective than a Single Dose in Preventing Diabetes in Non-Obese Diabetic (NOD) Mice,”Israel Journal of Medical Sciences33:711-715 (1997).
Singh and Elliot, “Can Progression of IDDM be Prevented in Newly Diagnosed Patients by BCG Immunotherapy?”Diabetes/Metabolism Reviews13(4):320-321 (1997).
Yagi et al., “Possible Mechanism of the Preventive Effect of BCG Against Diabetes Mellitus in NOD Mouse. I. Generation of Suppressor Macrophages in Spleen Cells of BCG-Vaccinated Mice,”Cellular Immunology138:130-141 (1991).
Yagi et al., “Possible Mechanism of the Preventive Effect of BCG Against Diabetes Mellitus in NOD Mouse. II. Suppression of Pathogenesis by Macrophage Transfer from BCG-Vaccinated Mice,”Cellular Immunology138:142-149 (1991).
Yang et al., “Effect of Tumor Necrosis Factor α on Insulin-dependent Diabetes Mellitus in NOD Mice. I. The Early Development of Autoimmunity and the Diabetogenic Process,”The Journal of Experimental Medicine180:995-1004 (1994).
Hartwell et al., “Aberrant Cytokine Regulation in Macrophages from Young Autoimmune-Prone Mice: Evidence that the Intrinsic Defect in MRL Macrophage IL-1 Expression is Transcriptionally Controlled,”Mol. Imm.32: 743-751, 1995.
Hayashi et al., “NOD Mice are Defective in Proteasome Production and Activation of NF-kB,”Mol. Cell. Biol.19: 8646-8659, 1999.
Rolfe et al., “The Ubiquitin-Mediated Proteolytic Pathway as a Therapeutic Area,”J. Mol. Med.75: 5-17, 1997.
Yan et al., “Reduced Expression of Tap 1 and Lmp2 Antigen-Processing Genes in the Nonobese Diabetic (NOD) Mouse Due to a Mutation in Their Shared Bidirectional Promoter,”J. Immun.159: 3068-3080, 1997.
Baxter et al., “Mycobacteria Precipitate an SLE-Like Syndrome in Diabetes-Prone NOD Mice,”Immunology83:227-231
Boesen Agnieszka
Clark & Elbing LLP
Helms Larry R
The General Hospital Corporation
LandOfFree
Treatment of autoimmune disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of autoimmune disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of autoimmune disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4166151